CytoMed Therapeutics (GDTC) Total Current Liabilities (2021 - 2025)

CytoMed Therapeutics has disclosed Total Current Liabilities across 5 years of filings, most recently posting $547179.2 for Q4 2025.

• In Q4 2025, Total Current Liabilities rose 19.98% year-over-year to $547179.2; the TTM figure through Dec 2025 stood at $547179.2 (up 19.98% YoY), while the FY2025 annual figure was $542797.0, up 19.02% from the prior year.
• Total Current Liabilities came in at $547179.2 for Q4 2025 at CytoMed Therapeutics, down from $703092.0 in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $3.0 million in Q4 2022 to a low of $314878.0 in Q2 2023.
• Average Total Current Liabilities over 5 years is $1.0 million, with a median of $539106.7 recorded in 2025.
• Year-over-year, Total Current Liabilities sank 82.31% in 2023 and jumped 96.44% in 2025.
• Over 5 years, Total Current Liabilities stood at $2.2 million in 2021, then surged by 38.7% to $3.0 million in 2022, then slumped by 82.31% to $531034.3 in 2023, then slipped by 14.12% to $456044.1 in 2024, then gained by 19.98% to $547179.2 in 2025.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $547179.2 in Q4 2025, $703092.0 in Q2 2025, and $456044.1 in Q4 2024.